Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Yannick, De Vlaeminck"'
Autor:
Bart Neyns, Sandra Tuyaerts, Ivan Van Riet, Karine Breckpot, Fien Meeus, Cyprine Neba Funeh, Robin Maximilian Awad, Katty Zeven, Dorien Autaers, Ann De Becker, Cleo Goyvaerts, Nick Devoogdt, Yannick De Vlaeminck
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 11 (2024)
Background Glioblastoma is the most common lethal primary brain tumor, urging evaluation of new treatment options. Chimeric antigen receptor (CAR)-T cells targeting B7 homolog 3 (B7-H3) are promising because of the overexpression of B7-H3 on glioblas
Externí odkaz:
https://doaj.org/article/3d6525de79f345cf86934422d3e6824d
Autor:
Robin Maximilian Awad, Yannick De Vlaeminck, Fien Meeus, Thomas Ertveldt, Katty Zeven, Hannelore Ceuppens, Cleo Goyvaerts, Magali Verdonck, Gustavo Salguero, Geert Raes, Nick Devoogdt, Karine Breckpot
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Blockade of the immune checkpoint axis consisting of programmed death-1 (PD-1) and its ligand PD-L1 alleviates the functional inhibition of tumor-infiltrating lymphoid cells yet weakly induces their expansion. Exogenous cytokines could furth
Externí odkaz:
https://doaj.org/article/9fb28e6fbf3b4facb292f00890c954cc
Autor:
Heleen Hanssens, Fien Meeus, Yannick De Vlaeminck, Quentin Lecocq, Janik Puttemans, Pieterjan Debie, Timo W. M. De Groof, Cleo Goyvaerts, Kim De Veirman, Karine Breckpot, Nick Devoogdt
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionMultiple myeloma (MM) remains incurable, despite the advent of chimeric antigen receptor (CAR)-T cell therapy. This unfulfilled potential can be attributed to two untackled issues: the lack of suitable CAR targets and formats. In relation
Externí odkaz:
https://doaj.org/article/3d9c11bb3b93466ea2e047b61538c6b5
Autor:
Robin Maximilian Awad, Quentin Lecocq, Katty Zeven, Thomas Ertveldt, Lien De Beck, Hannelore Ceuppens, Katrijn Broos, Yannick De Vlaeminck, Cleo Goyvaerts, Magali Verdonck, Geert Raes, Alexander Van Parys, Anje Cauwels, Marleen Keyaerts, Nick Devoogdt, Karine Breckpot
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 22, Iss , Pp 172-182 (2021)
Monoclonal antibodies that target the inhibitory immune checkpoint axis consisting of programmed cell death protein 1 (PD-1) and its ligand, PD-L1, have changed the immune-oncology field. We identified K2, an anti-human PD-L1 single-domain antibody f
Externí odkaz:
https://doaj.org/article/a02773e0d7c64fbda016a0f01cb0fe31
Autor:
Lien De Beck, Robin Maximilian Awad, Veronica Basso, Noelia Casares, Kirsten De Ridder, Yannick De Vlaeminck, Alessandra Gnata, Cleo Goyvaerts, Quentin Lecocq, Edurne San José-Enériz, Stefaan Verhulst, Ken Maes, Karin Vanderkerken, Xabier Agirre, Felipe Prosper, Juan José Lasarte, Anna Mondino, Karine Breckpot
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Immunotherapy has improved the treatment of malignant skin cancer of the melanoma type, yet overall clinical response rates remain low. Combination therapies could be key to meet this cogent medical need. Because epigenetic hallmarks represent promis
Externí odkaz:
https://doaj.org/article/f6044c9296d648419688c29e75e4e1a4
TNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy
Autor:
Kirsten De Ridder, Hanne Locy, Elisa Piccioni, Miren Ibarra Zuazo, Robin Maximilian Awad, Stefaan Verhulst, Mathias Van Bulck, Yannick De Vlaeminck, Quentin Lecocq, Eva Reijmen, Wout De Mey, Lien De Beck, Thomas Ertveldt, Isabel Pintelon, Jean-Pierre Timmermans, David Escors, Marleen Keyaerts, Karine Breckpot, Cleo Goyvaerts
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Immune checkpoint blockade (ICB) of the PD-1 pathway revolutionized the survival forecast for advanced non-small cell lung cancer (NSCLC). Yet, the majority of PD-L1+ NSCLC patients are refractory to anti-PD-L1 therapy. Recent observations indicate a
Externí odkaz:
https://doaj.org/article/8cb0f64de304414d9efd07fa0701e7a3
Autor:
Ahmet Krasniqi, Karine Breckpot, Matthias D'Huyvetter, Nick Devoogdt, Marleen Keyaerts, Robin Maximilian Awad, Yannick De Vlaeminck, Hannelore Ceuppens, Quentin Lecocq, Cleo Goyvaerts, Wout de Mey, Hanne Locy, Kirsten De Ridder, Lien De Beck, Thomas Ertveldt
Targeted radionuclide therapy (TRT) using probes labeled with Lutetium-177 (177Lu) represents a new and growing type of cancer therapy. We studied immunologic changes in response to TRT with 177Lu labeled anti-human CD20 camelid single domain antibod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a371709b35ee535482c91b0dd585fceb
https://doi.org/10.1158/1535-7163.c.6543403.v1
https://doi.org/10.1158/1535-7163.c.6543403.v1
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Tumor cells frequently produce soluble factors that favor myelopoiesis and recruitment of myeloid cells to the tumor microenvironment (TME). Consequently, the TME of many cancer types is characterized by high infiltration of monocytes, macrophages, d
Externí odkaz:
https://doaj.org/article/1ba3cb7c06d94c8b90094025482b5dbf
Autor:
Quentin Lecocq, Katty Zeven, Yannick De Vlaeminck, Sandrina Martens, Sam Massa, Cleo Goyvaerts, Geert Raes, Marleen Keyaerts, Karine Breckpot, Nick Devoogdt
Publikováno v:
Biomolecules, Vol 9, Iss 10, p 548 (2019)
Immune checkpoint inhibition (ICI) is a promising cancer therapy, which has progressed rapidly from a preclinical concept to clinical implementation. Commonly considered targets in ICI are CTLA-4, PD-1/PD-L1, and LAG-3, and the list grows. As ICI is
Externí odkaz:
https://doaj.org/article/2cad000699384e4e8bdccf532a675f49
Autor:
Robin Maximilian, Awad, Fien, Meeus, Hannelore, Ceuppens, Thomas, Ertveldt, Heleen, Hanssens, Quentin, Lecocq, Lukasz, Mateusiak, Katty, Zeven, Hana, Valenta, Timo W M, De Groof, Yannick, De Vlaeminck, Ahmet, Krasniqi, Kim, De Veirman, Cleo, Goyvaerts, Matthias, D'Huyvetter, Sophie, Hernot, Nick, Devoogdt, Karine, Breckpot
Publikováno v:
International review of cell and molecular biology. 369
Cancer is a heterogeneous disease, requiring treatment tailored to the unique phenotype of the patient's tumor. Monoclonal antibodies (mAbs) and variants thereof have enabled targeted therapies to selectively target cancer cells. Cancer cell-specific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5efb9206e5f2b488b5acb059570c4402
https://pubmed.ncbi.nlm.nih.gov/35777863
https://pubmed.ncbi.nlm.nih.gov/35777863